Head to Head Comparison: Catabasis Pharmaceuticals (NASDAQ:CATB) vs. Its Rivals

Catabasis Pharmaceuticals (NASDAQ: CATB) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Catabasis Pharmaceuticals to related companies based on the strength of its earnings, dividends, analyst recommendations, valuation, institutional ownership, risk and profitability.

Risk and Volatility

Catabasis Pharmaceuticals has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Catabasis Pharmaceuticals’ rivals have a beta of 6.10, suggesting that their average stock price is 510% more volatile than the S&P 500.

Institutional & Insider Ownership

33.1% of Catabasis Pharmaceuticals shares are held by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 40.7% of Catabasis Pharmaceuticals shares are held by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Catabasis Pharmaceuticals and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Catabasis Pharmaceuticals N/A -$36.06 million -1.11
Catabasis Pharmaceuticals Competitors $284.30 million $34.29 million 137.84

Catabasis Pharmaceuticals’ rivals have higher revenue and earnings than Catabasis Pharmaceuticals. Catabasis Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and target prices for Catabasis Pharmaceuticals and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catabasis Pharmaceuticals 0 1 5 0 2.83
Catabasis Pharmaceuticals Competitors 843 3191 11572 230 2.71

Catabasis Pharmaceuticals presently has a consensus price target of $5.33, indicating a potential upside of 217.46%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.51%. Given Catabasis Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Catabasis Pharmaceuticals is more favorable than its rivals.


This table compares Catabasis Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Catabasis Pharmaceuticals N/A -135.85% -95.96%
Catabasis Pharmaceuticals Competitors -5,338.36% -435.70% -40.49%

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company’s primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company’s CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company’s CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.

Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply